Ishiyama Asuka, Jang Hee-Seong, Dintaman Jay M, Duess Johannes W, Tragesser Cody, Sodhi Chhinder P
Department of Pediatric General and Urogenital Surgery, Johns Hopkins University School of Medicine, Tokyo 113-8421, Japan.
Division of Pediatric Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Biomedicines. 2025 Sep 17;13(9):2288. doi: 10.3390/biomedicines13092288.
This review integrates clinical, immunological, microbial, pathophysiological, and therapeutic perspectives on necrotizing enterocolitis (NEC)-a leading cause of morbidity and mortality in premature infants. We summarize the clinical burden and risk factors; elucidate key immune and cellular mechanisms, including TLR4 signaling, epithelial barrier dysfunction, and enteric nervous system involvement; and provide a concise overview of experimental models. We also highlight microbial dysbiosis, ischemia, multiorgan injury, and recent advances in pathogenesis, as well as current and emerging therapies such as probiotics, breast milk components, TLR4 inhibitors, and immunomodulators, emphasizing the need for a multidisciplinary approach to accelerate discovery and improve outcomes. Overall, this review bridges mechanistic insights to clinical applications and supports the pursuit of personalized NEC prevention.
本综述整合了关于坏死性小肠结肠炎(NEC)的临床、免疫学、微生物学、病理生理学及治疗学观点,坏死性小肠结肠炎是早产儿发病和死亡的主要原因。我们总结了临床负担和风险因素;阐明了关键的免疫和细胞机制,包括Toll样受体4(TLR4)信号传导、上皮屏障功能障碍和肠神经系统受累情况;并简要概述了实验模型。我们还强调了微生物群落失调、缺血、多器官损伤及发病机制的最新进展,以及益生菌、母乳成分、TLR4抑制剂和免疫调节剂等现有及新兴疗法,强调需要采用多学科方法来加速研究发现并改善治疗效果。总体而言,本综述将机制性见解与临床应用联系起来,支持开展个性化的坏死性小肠结肠炎预防工作。